Retatrutide vs Setmelanotide
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Retatrutide or Setmelanotide?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Retatrutide and Setmelanotide?
Setmelanotide targets MC4R specifically in patients with rare genetic lesions (population of thousands globally); retatrutide targets GLP-1/GIP/glucagon receptors in common obesity (population of hundreds of millions) - different mechanisms for fundamentally different patient populations.
Evidence Comparison
Setmelanotide (Imcivree): FDA approved for specific genetically confirmed obesity syndromes, with large effects in a narrow population. Retatrutide: five positive sponsor-reported Phase 3 studies but no approval. Setmelanotide has the regulatory advantage; retatrutide targets a much broader obesity population.
Evidence Context Favoring Retatrutide
Common obesity research where triple agonist pharmacology and >20% weight loss are the focus, accepting Phase 2 evidence.
Evidence Context Favoring Setmelanotide
Genetically confirmed POMC/PCSK1/LEPR deficiency obesity where setmelanotide is the only approved targeted therapy.
Side-by-Side Snapshot
| Evidence grade | Retatrutide: Level B Setmelanotide: Level A |
|---|---|
| Research status | Retatrutide: Phase 3 Setmelanotide: FDA Approved |
| Primary category | Retatrutide: Weight Loss & Metabolic Setmelanotide: Weight Loss & Metabolic |
| Cited studies | Retatrutide: 5 Setmelanotide: 2 |